SVR, n = 72 | Non-SVR, n = 74 | P values (SVR versus non-SVR groups) | |
---|---|---|---|
Gender, male/female | 39/33 | 34/40 | 0.40 |
Age, years | 54.4 ± 12.7 | 57.0 ± 9.3 | 0.15 |
Previous treatment: naïve/relapse/null | 59/12/1 | 43/14/17 | 0.00020 |
AST, IU/L | 54.1 ± 54.3 | 61.8 ± 42.5 | 0.34 |
ALT, IU/L | 69.0 ± 71.5 | 73.0 ± 58.2 | 0.71 |
γ-GTP, IU/L | 42.7 ± 41.3 | 70.0 ± 85.7 | 0.0158 |
Hemoglobin, g/dL | 13.9 ± 1.1 | 14.1 ± 1.3 | 0.31 |
Platelets, ×104/mm3 | 17.8 ± 5.4 | 15.7 ± 5.9 | 0.0265 |
Treatment response | |||
RVR, n | 15 | 0 | 0.000107 |
EVR, n | 53 | 12 | <0.0001 |
IFNL4, ss469415590, major/minor/ND |
60/10/2 | 33/38/3 | <0.0001 |
Null: null response; AST: aspirate aminotransferase; ALT: alanine aminotransferase; γ-GTP: γ-glutamyltransferase; RVR: rapid virological response; EVR: early virological response; SVR: sustained virological response.